Catheter Precision, Inc. (NYSE American: VTAK) Reports Q2 2024 Preliminary Revenue

Catheter Precision, Inc., a MedTech company in cardiac electrophysiology, reports preliminary unaudited revenue for Q2 2024. The company recorded its first sales of LockeT, resulting in $40,500 in revenue. Additional sales of VIVO products accounted for $54,340. Total revenue for the quarter ended June 30, 2024, reached $94,840, with six-month revenue totaling $176,923.

CEO David Jenkins commented, "We are pleased to announce these preliminary unaudited revenues. The initial results of our new sales team, led by Chief Commercial Officer Marie Claude Jaques, are promising. A growing pipeline of potential customers provides insights for future growth."